- EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO
- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys AG Reports First Quarter 2024 Financial Results
- EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
- EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
More ▼
Key statistics
As of last trade MorphoSys AG (MOR:FRA) traded at 67.75, -3.42% below its 52-week high of 70.15, set on May 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 67.60 |
---|---|
High | 67.85 |
Low | 67.60 |
Bid | 67.75 |
Offer | 67.90 |
Previous close | 67.55 |
Average volume | 2.93k |
---|---|
Shares outstanding | 37.72m |
Free float | 6.55m |
P/E (TTM) | -- |
Market cap | 2.59bn EUR |
EPS (TTM) | -12.54 EUR |
Data delayed at least 15 minutes, as of Jun 07 2024 12:33 BST.
More ▼